Key facts
- This page summarizes Versant Ventures V, LLC's Form 4 filing for Turnstone Biologics Corp. (TSBX).
- 5 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 12 Aug 2025, 16:34.
Versant Ventures V, LLC - 08 Aug 2025 Form 4 Insider Report for Turnstone Biologics Corp. (TSBX)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- TSBX
- Reported as of
- 08 Aug 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Aug 2025, 16:34:57 UTC
- Prior SEC filing
- 27 Jul 2023
- Source filing
- View source filing
- Reporting owner signature
- Versant Ventures V, LLC, By /s/ Max Eisenberg, Chief Operating Officer
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Versant Ventures V, LLC filed Form 4 for Turnstone Biologics Corp. (TSBX) on 12 Aug 2025.
Change
- Previous filing in this sequence was filed on 27 Jul 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (10)
CIK 0001619298
Primary reporting owner
Versant Ventures V, LLC
- Relationship
- 10%+ Owner
- Address
- ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO
- Signature
- Versant Ventures V, LLC, By /s/ Max Eisenberg, Chief Operating Officer
- Signature date
- 12 Aug 2025
CIK 0001589097
Versant Venture Capital V, L.P.
- Relationship
- 10%+ Owner
- Address
- ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO
- Signature
- Versant Venture Capital V, L.P., By Versant Ventures V, LLC, its general partner, By /s/ Max Eisenberg, Chief Operating Officer
- Signature date
- 12 Aug 2025
CIK 0001589098
Versant Ophthalmic Affiliates I, L.P.
- Relationship
- 10%+ Owner
- Address
- ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO
- Signature
- Versant Ophthalmic Affiliates Fund I, L.P., By Versant Ventures V, LLC, its general partner, By /s/ Max Eisenberg, Chief Operating Officer
- Signature date
- 12 Aug 2025
CIK 0001589095
Versant Affiliates Fund V, L.P.
- Relationship
- 10%+ Owner
- Address
- ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO
- Signature
- Versant Affiliates Fund V, L.P., By Versant Ventures V, LLC, its general partner, By /s/ Max Eisenberg, Chief Operating Officer
- Signature date
- 12 Aug 2025
CIK 0001619297
Versant Ventures V GP-GP (Canada), Inc.
- Relationship
- 10%+ Owner
- Address
- ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO
- Signature
- Versant Ventures V GP-GP (Canada), Inc., By /s/ Max Eisenberg, Chief Operating Officer
- Signature date
- 12 Aug 2025
CIK 0001716490
Versant Ventures V (Canada), L.P.
- Relationship
- 10%+ Owner
- Address
- ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO
- Signature
- Versant Ventures V (Canada), L.P., By Versant Ventures V GP-GP (Canada), Inc., its general partner, By /s/ Max Eisenberg, Chief Operating Officer
- Signature date
- 12 Aug 2025
CIK 0001612235
Versant Venture Capital V (Canada), LP
- Relationship
- 10%+ Owner
- Address
- ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO
- Signature
- Versant Venture Capital V (Canada), LP, By Versant Ventures V (Canada), L.P., its general partner, By Versant Ventures V GP-GP (Canada), Inc., its general partner, By /s/ Max Eisenberg, Chief Operating Officer
- Signature date
- 12 Aug 2025
CIK 0001839789
Versant Vantage II GP-GP, LLC
- Relationship
- 10%+ Owner
- Address
- ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO
- Signature
- Versant Vantage II GP-GP, LLC, By /s/ Max Eisenberg, Chief Operating Officer
- Signature date
- 12 Aug 2025
CIK 0001839790
Versant Vantage II GP, L.P.
- Relationship
- 10%+ Owner
- Address
- ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO
- Signature
- Versant Vantage II GP, L.P., By Versant Vantage II GP-GP, LLC, its general partner, By /s/ Max Eisenberg, Chief Operating Officer
- Signature date
- 12 Aug 2025
CIK 0001832235
Versant Vantage II, L.P.
- Relationship
- 10%+ Owner
- Address
- ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO
- Signature
- Versant Vantage II, L.P., By Versant Vantage II GP, L.P., its general partner, By Versant Vantage II GP-GP, LLC, its general partner, By /s/ Max Eisenberg, Chief Operating Officer
- Signature date
- 12 Aug 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TSBX
transaction
Common Stock
Disposition pursuant to a tender of shares in a change of control transaction
- Transaction value
- Shares
- -2,726,322
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 08 Aug 2025
- Ownership
- By Versant Venture Capital V, L.P.
- Footnotes
- F1, F2
TSBX
transaction
Common Stock
Disposition pursuant to a tender of shares in a change of control transaction
- Transaction value
- Shares
- -207,486
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 08 Aug 2025
- Ownership
- By Versant Venture Capital V (Canada) LP
- Footnotes
- F1, F3
TSBX
transaction
Common Stock
Disposition pursuant to a tender of shares in a change of control transaction
- Transaction value
- Shares
- -90,888
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 08 Aug 2025
- Ownership
- By Versant Ophthalmic Affiliates Fund I, L.P.
- Footnotes
- F1, F4
TSBX
transaction
Common Stock
Disposition pursuant to a tender of shares in a change of control transaction
- Transaction value
- Shares
- -82,006
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 08 Aug 2025
- Ownership
- By Versant Affiliates Fund V, L.P.
- Footnotes
- F1, F5
TSBX
transaction
Common Stock
Disposition pursuant to a tender of shares in a change of control transaction
- Transaction value
- Shares
- -274,990
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 08 Aug 2025
- Ownership
- By Versant Vantage II, L.P.
- Footnotes
- F1, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Versant Ventures V, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 6 footnotes
Footnote F1
Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest.
Footnote F2
Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis ("Dr. Davis"), a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Versant V, and each disclaims beneficial ownership of the shares held by Versant V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
Footnote F3
Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Dr. Davis, a member of the Issuer's board of directors, is a director of Canada V GP-GP. Each of Canada V GP-GP, Canada V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Canada V, and each disclaims beneficial ownership of the shares held by Canada V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
Footnote F4
Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Ophthalmic, and each disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
Footnote F5
Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Affiliates V, and each disclaims beneficial ownership of the shares held by Affiliates, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
Footnote F6
Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the sole general partner of Vantage II GP. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP. Each of Vantage II GP-GP, Vantage II GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Vantage II, and each disclaims beneficial ownership of the shares held by Canada V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.